The selling is small relative to market cap and partly plan-driven, but the breadth (6 insiders including directors and EVPs) and the discretionary sales by Sing and Poon post-earnings suggest insiders are taking profits after the stock's strong run. Monitor for any acceleration of selling in the next 30 days.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $904.35entry
- T+1 · 8d ago +1.73%α −0.64% · $919.96
- T+5 · 4d ago +5.65%α +3.06% · $955.47
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Six Regeneron insiders, including the CFO and multiple directors, sold a total of $11.28M in open-market sales over a week following a strong Q3 earnings beat. The cluster includes both 10b5-1 plan sales and discretionary sales, with the largest single sale ($6.83M) by director George L. Sing. While the dollar amount is modest relative to Regeneron's $100.7B market cap (0.011%), the breadth of selling across C-suite and board members warrants attention.
Key Financial Metrics
Key Facts
- Six insiders sold shares in open-market transactions totaling $11.28M over the week ending November 3, 2026
- The largest sale was by director George L. Sing: 7,073 shares at $965.38 for $6.83M on November 2
- CFO Christopher R. Fenimore exercised 6,000 derivative shares at $0 (non-cash) but had no open-market sale listed
- Three insiders (Brown, McCourt, Guarini) sold under 10b5-1 plans; three (Poon, Sing, LaRosa) sold without a plan
- Total open-market sales represent approximately 0.011% of Regeneron's $100.7B market cap
- The cluster follows Regeneron's Q3 2026 earnings release on October 30, which showed revenue of $5.116B (up 36% YoY) and GAAP EPS of $18.45 (up 35% YoY)
Financial Impact
Total open-market insider sales of $11.28M, or 0.011% of market cap
Risk Factors
- Insider selling after a strong earnings beat may signal that the stock is fully valued near current levels
- Discretionary sales by directors without 10b5-1 plans carry more weight than plan sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-REGN-1793912770489 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Viewing Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers